Back to mobile site
Get it on Google Play

FDA approves expanded TREMFYA label for joint damage prevention

May 28, 2026 7:10 PM EDT Send to a Friend
Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration approved a supplemental Biologics License Application to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login